NEW IN CANADA, this Fuji's mammography system offers SMARTER patient comfort, departmental workflow, and image quality.
Built to perform, Asprire Cristalle, digital breast tomosynthesis offers a patented comfort design for a better patient experience, a superior diagnostic accuracy for radiologists, and fast, easy to use, reliable workflow.
Fujifilm’s Aspire Cristalle includes:
Adaptative image processing. To produce consistent image quality across the wide range of patients, ASPIRE Cristalle incorporates image processing algorithms that automatically “adapt” to patients breast thickness and composition. Using analytical processes similar to those used with iAEC, these algorithms localize the glandular regions in the acquired image, assess their contrast, and if needed, make minor adjustments to default processing parameters.
Iterative Super-Resolution (ISR) reconstruction generates inital slice images; simulated projection images from the slice images; and compares the simulated projection images to the actual projection images. ISR also calculates the amount of error, and generates in slice images to decrease this amount of error.
Twice faster with a 15 seconds 2D cycle time
Image based Spectrum Conversion (ISC) By performing an analysis of the energy distributions between the two types of target materials, Fujifilm has developed an image processing algorithm that takes advantage of W target’s lowest dose imaging, while, at the same time, providing the high contrast images of Mo. ASPIRE Cristalle introduces this new feature.
Hexagonal Close Pattern Detector. By utilizing innovative hexagonal pixels, the electric field between them is considerably stronger and they improve the information capture.
Intelligent Automatic Exposure Control that performs a detailed analysis of the pre-exposure image to determine the optimum exposure conditions for the view.
Three dose modes (H, N, andL) that can be selected by the technologist (Nmode is typically used). These modes coupled with the increased sensitivity of its HCP detector and improved dose stabilization of its iAEC method, enable ASPIRE Cristalle to demonstrate reduced patient dose when compared to a competitive FFDM system.
Dynamic Vision II locates pectoral muscle and implants to exclude them from further analysis. It also identifies glandular and adipose tissues, and features. DVII applies MFP2 processing for edge enhancement & dynamic range control, and offers better conspicuity of microcalcifications, improved visibility and morphology of masses compared to conventional processing due to 50 mm pixel output, lower exposure dose to patients and DVII image processing.
Tomosynthesis has an X-ray tube that moves through an arc, acquiring a series of low-dose images at different angles, and then, reconstruct them into a series of high-resolution slices which are 1 millimeter apart. This reconstruction makes it easier to identify lesions.
Comfort paddle gently adapts to the breast, allows for firmer, more tolerable compression and plate to flex and contour to the breast. It also distributes pressure evenly, for more even distribution of breast tissue.
Reliability & dependability through one shot quality control program that provides all phantom materials and software support needed for QC Technologist and Medical Physicist testing; and allows for trending and print out of accumulated weekly, quarterly, semiannual & annual QC test results.
Our Stereotactic Positioner delivers simplified needle placement and visualization for improved diagnostic confidence.
The attributes that make DBT so valuable to your clinical practice cause pressure on your IT. The enormous datasets can cause significant study management challenges, making it imperative that you consider your IT strategy carefully.
Our Synapse® Enterprise Imaging portfolio – including Synapse 5 PACS and Synapse VNA – enables secure, easy-to-manage storage and access to the complete patient imaging record, and this, throughout the healthcare enterprise. Our Synapse 5 server-side rendering technology is ideally suited to handle the massive datasets generated by DBT exams—enabling unprecedented image-rendering speed, a reduced burden on IT infrastructure and increased speed to diagnosis. It immediately output individual images to PACS, viewer, or printer during exam , and improves system availability and extend system life with programmable automatic startup, sleep, and shutdown.
The detector is the heart of any digital mammography system. Simply put, its job is to detect X-rays, convert them into electrons, and collect the resulting electrical charges. The more efficiently it collects charges, the stronger the image signal, the less noisy the image, and the lower the dose needed.
In conventional detector design, the pixels that detect X-rays are square, with wide gaps between them, losing some of the converted X-ray information.
Introducing Hexagonal Close Pattern (HCP) pixel design. In the Aspire Cristalle, hexagonal pixels are arranged with smaller gaps between pixels, resulting in less signal loss, stronger electrical fields, and higher sensitivity. When compared to square pixels, HCP delivers:
ASPIRE Cristalle is built with Intelligent Automatic Exposure Control (iAEC). iAEC intelligently analyzes breast composition and thickness and applies auto-recognition of implants. This optimizes dose and processing to generate exceptional images at low doses for all breast types, including breasts with implants.
In every woman’s life, there are moments where imaging will make the difference. Where wellness, peace of mind, and even life are on the line and the unique insights offered by radiology provide answers.
That’s where you’ll find Fujifilm.
With over 80 years of imaging breakthroughs, over 9,000 global ASPIRE digital mammography installations and an unrelenting drive to discover what’s next, we continually deliver value from innovation. Our advanced technologies, such as ASPIRE Cristalle 3D mammography, enable and empower. Doctors can see and strive to make the most accurate diagnoses. Practices can run more efficiently. And patients can determine their best path forward.
We are proud to contribute to these victories against disease and doubt. Whether large or small, they can change a woman’s life. And as needs evolve, we’ll be here. Acting on insights, driving innovation, inspiring hope—and together with our customers, having a lasting and profound effect on women’s health.